{"contentid": 488666, "importid": NaN, "name": "BlueRock in ophthalmology R&D alliance", "introduction": "The Bayer subsidiary BlueRock Therapeutics and FUJIFILM Cellular Dynamics (FCDI), a developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, have teamed up with Opsis Therapeutics.", "content": "<p>The Bayer (BAYN: DE) subsidiary BlueRock Therapeutics and FUJIFILM Cellular Dynamics (FCDI), a developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, have teamed up with Opsis Therapeutics.</p>\n<p>Focused on advancing the pipeline of cell replacement therapies targeting ocular diseases, Opsis is a joint venture of FCDI and David Gamm, a practicing pediatric ophthalmologist at the University of Wisconsin-Madison.</p>\n<h2>Combining collective expertise</h2>\n<p>The companies have entered into a strategic research and development (R&amp;D) alliance, as part of which they will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases.</p>\n<p>Under this agreement, BlueRock will have the option to exclusively license from both parties three retinal cell therapy programs focused on dry age-related macular degeneration (AMD) and inherited retinal diseases (IRDs) containing human retinal pigment epithelial cells and photoreceptor cells, currently in pre-clinical development.</p>\n<p>Emile Nuwaysir, president and chief executive, BlueRock, said: &ldquo;We believe deeply that authentic cells are the breakthrough approach needed to treat degenerative retinal diseases like AMD and IRDs.</p>\n<p>&ldquo;This strategic alliance between BlueRock Therapeutics, Opsis Therapeutics, and FCDI will allow each party to do what they do best, and when combined with our deep expertise in ophthalmology at Bayer, we are well-positioned to lead in this rapidly advancing field and potentially make a meaningful difference in millions of people&rsquo;s lives.&rdquo;</p>\n<h2>'Reverse the progression of ocular diseases'</h2>\n<p>Takeshi Yamamoto, chief executive of FCDI, which is part of Fujifilm Holdings Corporation (TYO: 4901), said: &ldquo;This alliance will leverage FCDI and Opsis Therapeutics&rsquo; combined expertise in iPS cell technologies and understanding of retinal diseases, with BlueRock Therapeutics&rsquo; experience in research and development of cell therapies, to provide next-generation ocular treatments.</p>\n<p>&ldquo;We are excited to team with BlueRock Therapeutics to discover and develop cell therapies to reverse the progression of ocular diseases and restore vision for patients impacted by these conditions.&rdquo;</p>\n<p>Under the terms of the agreement, FCDI and Opsis will receive an upfront payment of $30 million and up to $40 million R&amp;D, along with some of the manufacturing funding for the development of three candidate programs.</p>\n<p>BlueRock will have the option to license the three programs on a program-by-program basis and will be responsible for development and commercialization of the licensed products.</p>\n<p>FCDI and BlueRock will share manufacturing responsibilities, with the former company dealing with clinical supply and both sharing responsibility for commercial supply.</p>\n<p>As per the agreement, FCDI and Opsis will be eligible to receive payments upon achievement of certain development and commercial milestones, as well as tiered high single-digit/low double-digit royalty payments on a per-program basis.</p>", "date": "2021-05-18 21:23:00", "meta_title": NaN, "meta_keywords": "BlueRock, Therapeutics, FCDI, cell, Opsis, diseases, alliance, retinal, development, ocular, human, Bayer, therapies, expertise, technologies, ophthalmolog", "meta_description": "The Bayer subsidiary BlueRock Therapeutics and FUJIFILM Cellular Dynamics (FCDI), a developer and manufacturer of human induced pluripotent stem (iPS) cell tech", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-18 18:25:06", "updated": "2021-05-18 21:23:26", "access": NaN, "url": "https://www.thepharmaletter.com/article/bluerock-in-ophthalmology-r-d-alliance", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "bluerock_big.png", "image2id": "bluerock_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Cell and Gene Therapy, Ophthalmics", "topic_tag": "Deals, Licensing, Research", "geography_tag": "Germany, Japan, USA", "company_tag": "Bayer, BlueRock Therapeutics, FUJIFILM Cellular Dynamics, Fujifilm Corp, FUJIFILM Holdings Corporation, Opsis Therapeutics", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-18 21:23:00"}